Roche/Chugai Hand in Hand in Haemophilia A
At Roche, our aim is to improve the health, quality of life and wellbeing of people around the world. We have been advancing medical science for over 120 years and are the world’s largest biotechnology company and a pioneer in the development of monoclonal antibodies (mAb). Chugai Pharma became a member of the Roche Group in 2002. Together, we aim to add exceptional value through the creation of innovative medical products and services for the benefit of the medical community and health around the world.
See our websites for further information:
At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. You can find more information about Sobi at www.sobi.com
About Bayer in Hemophilia
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. We are driven by helping people with hemophilia thrive. Over the past 30 years, we’ve developed a deep understanding of the evolving aspirations of people with hemophilia. Bayer’s portfolio of rFVIII treatments offer hemophilia patients a treatment to suit their individual needs and lifestyles. For more information, go to www.bayer.com.
Daiichi – Sankyo
With a legacy of more than 100 years of scientific expertise and its corporate origin in Japan, Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
LumiraDx recognises the need to provide more effective, cost-efficient healthcare for everyone. We make diagnostic-led care simpler and more accessible with smarter connected diagnostics and diagnostic-led care solutions to enable better outcomes: better health, better experiences and better value. LumiraDx has over 400 employees worldwide with head offices in London, UK and Waltham, USA. For more information, go to www.lumiradx.com
Sanofi Genzyme, the Specialty Care Business Unit of Sanofi, focuses on Rare Diseases, Multiple Sclerosis, Oncology, Immunology and Rare Blood Disorders. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Shionogi & Co. Ltd
From our beginnings over 140 years ago in Osaka, Japan, Shionogi & Co. Ltd. has built a strong heritage in research-based medicine, matched by world-class market access and patient insight capabilities. Shionogi Europe was launched in 2012 and is committed to applying our patient-first approach in everything we do.
Leading player specialised in Haemostasis, Stago develops and markets automated systems for blood analysis in coagulation: Headquarters in Paris; R&D, manufacturing and logistics activities mainly in Europe. Its products are available in 115 countries through a network of 21 subsidiaries and 94 distributors. Stago headcounts is 2,500 employees worldwide.
Sysmex Europe is a subsidiary of the Sysmex Corporation, a global top-ten IVD company. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science that make a difference in healthcare.
HYPHEN BioMed specialises in developing, manufacturing and distributing IVD and research reagents for exploring thrombosis and haemostasis. Together, we deliver a holistic approach to haemostasis testing.
For more information, go to www.sysmex-europe.com
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Technoclone is a leading producer of diagnostics tests, equipments and research products in the area of blood clotting. Furthermore Technoclone provides a complete range for ADAMTS-13 testing, a fully automated Thrombin Generation as well a complete portfolio for the new anticoagulants (DOAC´s) such as for Xa inhibitors and direct thrombin inhibitors.